case rePorTs

Case 1
A 2-year-old female child came with reddish lesion on the right side of face since birth [ Figure 1a ]. There was rapid increase in size to the current state where it had formed a large vascular nodule. The child had not received any treatment earlier. The lesion was not posttraumatic or associated with tenderness, discharge. General and systemic examination was normal. On cutaneous examination, there were soft compressible reddish nodules present over the right eyelid and eyebrow and extending onto the temporal area and lateral side of forehead, suggestive of hemangioma. There was associated narrowing of the right palpebral fissure because of the size of hemangioma leading to decreased vision. Due to the localization of the hemangioma over the right eyelid, there was imminent danger of amblyopia. As the site of hemangioma was difficult for surgical excision, we decided to start this patient on oral propranolol. The patient was treated over the course of 3 years intermittently with oral propranolol at the dose of 1 mg/kg/day for 3 days under supervision, with close monitoring of hypotension, bradycardia (by pulse oximeter), and hypoglycemia (by glucometer). Imaging was done in the form of two-dimensional (2D)-echo, which was normal. As there were no adverse effects noted, the dose was stepped up to 2 mg/kg/day. The patient tolerated the treatment well. There was rapid response within a week with regards to alteration in color and texture. At the end of 3 months [ Figure 1b ], significant improvement was noted, which continued till next 6 months [ Figure 1c ]. There was near total clearance of hemangioma at the end of 5 years [ Figure 1d ].
Case 2
A 3-month-old female child presented with lesions on genitals since first 2 weeks of life [ Figure 2a ]. The child had not received any treatment beforehand. The lesion was not posttraumatic or associated with tenderness, discharge. General and systemic examination was normal. On cutaneous examination, there was soft compressible vascular swelling over the right side of labia major an extending to right perianal region, suggestive of hemangioma. The site was not amenable to surgery due to its anatomical location. The patient was treated with oral propranolol at the dose of 1 mg/kg/day for 3 days under supervision, with close monitoring of hypotension, bradycardia (by pulse oximeter), and hypoglycemia (by glucometer). Imaging was done in the form of 2D-echo, which was normal. As there were no adverse effects noted, the dose was stepped up to 2 mg/kg/day and was given for 12 months. The patient tolerated the treatment well. Over the course of one year [Figures 2a-d], the lesion completely regressed with almost no scarring, with response being noted as early as 7 days.
Case 3
An 8-year-old female child came with lesions on dorsal and ventral surfaces of the tongue since first 2 weeks of life [ Figure 3a and b]. The lesions were associated with recurrent bleeding, not associated with pain or trauma. The general and systemic examination was normal. Cutaneous examination revealed multiple bluish-red vascular lesions on the tongue. As this site was difficult for surgical excision, we decided to start this patient on oral propranolol. The patient was given oral propranolol at 1 mg/kg/day for 3 days under supervision, with close monitoring of hypotension, bradycardia (by pulse oximeter), and hypoglycemia (by glucometer). Imaging was done in the form of 2D-echo, which was normal. As there were no adverse effects noted, the dose was stepped up to 2 mg/kg/day, for 6 months, with marked improvement in size [ Figure 3c and d]. The patient tolerated the treatment well, with response being noted within a week in the form of change in size and texture. There was no recurrence of hemangioma after discontinuation of propranolol. discUssion Propranolol, is a nonselective beta-blocker and if not contraindicated, stands as the first-line agent for hemangiomas that impair function or cause permanent disfigurement. [14] In 2014, propranolol hydrochloride oral solution was approved by the US Food and Drug Administration for the treatment of proliferating infantile hemangioma (IH) requiring systemic therapy. [15] Other modalities of treatment for IHs include oral steroids, vincristine, interferon alpha, surgery, and pulsed dye laser, but these are cumbersome and associated with variable side effects and complications. Surgical excision at times is not possible due to difficult anatomic sites and due to risk of cosmetic disfigurement.
The efficacy of propranolol in IHs was reported serendipitously by Léauté-Labrèze et al. in 2008 where the use of propranolol in their patient for hypertrophic myocardiopathy caused by corticosteroids lead to dramatic improvement in patient's hemangioma. [16] Propranolol inhibits the growth and induces regression of IHs by its potential mechanisms of inducing vasoconstriction, decreased expression of vascular endothelial growth factor and matrix metalloproteinases, and/or triggering of apoptosis. [16] [17] [18] The proposed mechanism of action of propranolol in hemangiomas included vasoconstriction, apoptosis of capillary endothelial cells, [19] and decreased the production of vascular endothelial growth factor and fibroblastic growth factor. During the growth phase, these latter two major pro-angiogenic factors are involved. Propranolol leads to decreased expression of genes related to them and down-regulation of the rapidly accelerated fibrosarcoma mitogen-activated protein kinase pathway [19] and the triggering of apoptosis of capillary endothelial cells. [20] Since then, due to its effects on vascular endothelium, it has been used to treat hemangiomas by many others and was found to be safe. [21] In rare instances, the drug has been reported to cause adverse effects such as hypoglycemia, bradycardia, hypotension, bronchospasm, [22] and high output cardiac failure in infants with very large hemangiomas. All our patients, however, showed no adverse effects, with dramatic regression of hemangioma clinically.
One must be careful using propranolol in cases of posterior fossa malformations, hemangiomas, arterial abnormalities, cardiac defects, eye abnormalities, sternal cleft, and supraumbilical raphe syndrome (PHACES syndrome) since potentially hypoperfusion of the brain is a small possibility.
Contraindications to the use of propranolol are reported to be cardiogenic shock, documented chronic and significant sinus bradycardia, documented chronic and significant hypotension, greater than first-degree heart block, heart failure, history of bronchospasm or wheezing, hypersensitivity to propranolol, and preterm infants with corrected age <5 weeks (postnatal age in weeks − number of weeks preterm). Our patients did not have any of these conditions and hence was administrated oral propranolol for a long duration of time.
As per conventional literature, the pretreatment evaluation should include detail history to rule out cardiovascular and respiratory abnormalities (e.g., poor feeding, dyspnea, tachypnea, diaphoresis, wheezing, heart murmur, and family history of heart block or arrhythmia). The thorough physical examination should be performed for cardiac or pulmonary assessment and measurement of heart rate and blood pressure.
Imaging studies including cardiac ultrasound or cardiac magnetic resonance imaging should be obtained in children with large facial hemangiomas at risk for PHACES to rule out the possibility of severe aortic coarctation, which is a contraindication for propranolol use. In these patients, baseline head and neck MRI with angiography are also preferred before propranolol unless the clinical situation requires urgent treatment (e.g., severe visual obstruction due to an orbital hemangioma). In such cases, propranolol can be initiated at a lower dose and slowly titrated up to a maximum dose of 1 mg/kg/day. [23] However, we could not perform these investigations due to lack of facilities. conclUsion Many treatment modalities are available to treat IHs. Of these, propranolol seems to be the most promising. However, more studies are needed to confirm the efficacy of propranolol before considering it as a possible first-line drug in the treatment of infantile hemangiomas.
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